These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38026755)

  • 1. Validation of 3- and 5-point severity scales to assess ARIA-E.
    Bracoud L; Klein G; Lyons M; Scelsi MA; Wojtowicz J; Bullain S; Purcell D; Fiebach JB; Barakos J; Suhy J
    Alzheimers Dement (Amst); 2023; 15(4):e12503. PubMed ID: 38026755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing ARIA-E severity scales and effects of treatment management thresholds.
    Klein G; Scelsi MA; Barakos J; Fiebach JB; Bracoud L; Suhy J; Delmar P; Lyons M; Wojtowicz J; Bullain S; Barkhof F; Purcell D
    Alzheimers Dement (Amst); 2022; 14(1):e12376. PubMed ID: 36474747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
    Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
    Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities.
    Bechten A; Wattjes MP; Purcell DD; Aliaga ES; Daams M; Brashear HR; Arrighi HM; Barkhof F
    J Neuroimaging; 2017 May; 27(3):318-325. PubMed ID: 28102639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
    Aldea R; Grimm HP; Gieschke R; Hofmann C; Lott D; Bullain S; Delmar P; Klein G; Lyons M; Piazza F; Carare RO; Mazer NA
    Alzheimers Dement (N Y); 2022; 8(1):e12306. PubMed ID: 35676943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
    Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
    J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies.
    Piazza F; Caminiti SP; Zedde M; Presotto L; DiFrancesco JC; Pascarella R; Giossi A; Sessa M; Poli L; Basso G; Perani D
    Neurology; 2022 Sep; 99(12):e1265-e1277. PubMed ID: 35940900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.
    Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Love N; Singhal A
    Radiol Case Rep; 2023 Jan; 18(1):275-279. PubMed ID: 36388611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion.
    Barkhof F; Daams M; Scheltens P; Brashear HR; Arrighi HM; Bechten A; Morris K; McGovern M; Wattjes MP
    AJNR Am J Neuroradiol; 2013 Aug; 34(8):1550-5. PubMed ID: 23436056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
    Withington CG; Turner RS
    Front Neurol; 2022; 13():862369. PubMed ID: 35401412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities.
    Sima DM; Phan TV; Van Eyndhoven S; Vercruyssen S; Magalhães R; Liseune A; Brys A; Frenyo P; Terzopoulos V; Maes C; Guo J; Hughes R; Gabr RE; Huijbers W; Saha-Chaudhuri P; Curiale GG; Becker A; Belachew S; Van Hecke W; Ribbens A; Smeets D
    JAMA Netw Open; 2024 Feb; 7(2):e2355800. PubMed ID: 38345816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR imaging features of amyloid-related imaging abnormalities.
    Barakos J; Sperling R; Salloway S; Jack C; Gass A; Fiebach JB; Tampieri D; Melançon D; Miaux Y; Rippon G; Black R; Lu Y; Brashear HR; Arrighi HM; Morris KA; Grundman M
    AJNR Am J Neuroradiol; 2013 Oct; 34(10):1958-65. PubMed ID: 23578674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
    Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
    J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
    Hampel H; Elhage A; Cho M; Apostolova LG; Nicoll JAR; Atri A
    Brain; 2023 Nov; 146(11):4414-4424. PubMed ID: 37280110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.
    Retout S; Gieschke R; Serafin D; Weber C; Frey N; Hofmann C
    Clin Pharmacol Ther; 2022 Apr; 111(4):857-866. PubMed ID: 35100444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.
    Menegaz de Almeida A; Leite M; Lopes LM; Gomes Lima P; Siegloch Barros ML; Rocha Pinheiro S; Andrade Í; Viana P; Morbach V; Marinheiro G; de Oliveira R; Pinheiro AC
    Expert Rev Neurother; 2024 Jun; ():1-8. PubMed ID: 38879828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
    Filippi M; Cecchetti G; Spinelli EG; Vezzulli P; Falini A; Agosta F
    JAMA Neurol; 2022 Mar; 79(3):291-304. PubMed ID: 35099507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.